TY - JOUR
T1 - Challenges in systematic reviews that evaluate drug efficacy or effectiveness
AU - Santaguida, P. Lina
AU - Helfand, Mark
AU - Raina, Parminder
PY - 2005/6/21
Y1 - 2005/6/21
N2 - Increasingly, consumers, clinicians, regulatory bodies, and insurers are using systematic reviews of drug interventions to select treatments and set policies. Although a systematic review cannot provide all the information a clinician needs to make an informed choice for therapy, it can help decision makers distinguish what claims about effectiveness are based on evidence, identify critical information gaps, describe features of the evidence that limit applicability in practice, and address whether drug effectiveness differs for particular subgroups of patients. To improve the relevance and validity of reviews of drug therapies, reviewers need to delineate clinically important subgroups, specific aims of therapy, and most important outcomes. They may need to find unpublished trials, studies other than direct comparator (head-to-head) trials, and additional details of published trials from pharmaceutical manufacturers and regulatory agencies. In this paper, we address ways to formulate questions relevant to specific clinical therapeutic aims; discuss types of studies to include in drug efficacy and effectiveness reviews and how to find them; and describe ways to assess applicability of studies to actual practice.
AB - Increasingly, consumers, clinicians, regulatory bodies, and insurers are using systematic reviews of drug interventions to select treatments and set policies. Although a systematic review cannot provide all the information a clinician needs to make an informed choice for therapy, it can help decision makers distinguish what claims about effectiveness are based on evidence, identify critical information gaps, describe features of the evidence that limit applicability in practice, and address whether drug effectiveness differs for particular subgroups of patients. To improve the relevance and validity of reviews of drug therapies, reviewers need to delineate clinically important subgroups, specific aims of therapy, and most important outcomes. They may need to find unpublished trials, studies other than direct comparator (head-to-head) trials, and additional details of published trials from pharmaceutical manufacturers and regulatory agencies. In this paper, we address ways to formulate questions relevant to specific clinical therapeutic aims; discuss types of studies to include in drug efficacy and effectiveness reviews and how to find them; and describe ways to assess applicability of studies to actual practice.
UR - http://www.scopus.com/inward/record.url?scp=20544459358&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=20544459358&partnerID=8YFLogxK
U2 - 10.7326/0003-4819-142-12_part_2-200506211-00006
DO - 10.7326/0003-4819-142-12_part_2-200506211-00006
M3 - Review article
C2 - 15968031
AN - SCOPUS:20544459358
SN - 0003-4819
VL - 142
SP - 1066
EP - 1072
JO - Annals of Internal Medicine
JF - Annals of Internal Medicine
IS - 12 II
ER -